Progesterone Receptor-positive Breast Cancer, Lobular Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma, HER2-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Estrogen Receptor-negative Breast Cancer, Ductal Breast Carcinoma in Situ, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer and Stage IIIC Breast Cancer Clinical Trial Using therapeutic conventional surgery, radiation therapy and quality-of-life assessment

- The folks at Roswell Park Cancer Institute are studying the effects of therapeutic conventional surgery; radiation therapy; quality-of-life assessment on Progesterone Receptor-positive Breast Cancer, Lobular Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma, HER2-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Estrogen Receptor-negative Breast Cancer, Ductal Breast Carcinoma in Situ, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer and Stage IIIC Breast Cancer in females ages 50 years and older. This clinical trial is slated to start May 2013.

Overall Study Contact Info
StatusName Contact Phone
Recruiting

This study is officially titled, "Phase II Trial of Single Fraction Radiation Therapy (SFRT) at Roswell Park Cancer Institute for Select Patients With Early Stage Breast Cancer."

Locations

Roswell Park Cancer Institute

Buffalo, New York - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.